Publication | Closed Access

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Atopic DermatitisModerate-to-severe Atopic DermatitisMulticentre Phase 3Clinical TrialsClinical DermatologyPharmacotherapyDermatologyAbrocitinib Versus DupilumabMedicine